Study NOG112264, a Phase II Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis
Phase of Trial: Phase II
Latest Information Update: 27 Dec 2017
At a glance
- Drugs Ozanezumab (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 10 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 02 Dec 2014 Planned End Date changed from 1 May 2015 to 1 Jan 2015 as reported by ClinicalTrials.gov record.
- 02 Dec 2014 Planned primary completion date changed from 1 May 2015 to 1 Nov 2014 as reported by ClinicalTrials.gov record.